FDA Approves Tremfya for Ulcerative Colitis

Follow Drugslib on

Medically reviewed by Drugs.com.

By Lori Solomon HealthDay Reporter

MONDAY, Sept. 16, 2024 -- The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis.

Tremfya is the first and only dual-acting interleukin-23 inhibitor approved in active ulcerative colitis. It is approved for administration as a 200-mg induction dose intravenously at weeks 0, 4, and 8 by a health care professional.

The approval is based on results from the phase 2b/3 QUASAR study. Half of patients receiving Tremfya 200 mg subcutaneous (SC) maintenance every four weeks and 45 percent of patients receiving Tremfya 100 mg SC every eight weeks achieved the primary end point of clinical remission at week 44 versus 19 percent of patients receiving placebo. At one year, 34 percent (200 mg) and 35 percent (100 mg) of patients achieved endoscopic remission compared with15 percent receiving placebo.

"Treatment with Tremfya resulted in significant improvement in the chronic symptoms of ulcerative colitis, and importantly, normalization in the endoscopic appearance of the intestinal lining," David T. Rubin, M.D., from the University of Chicago Medicine and lead investigator for the QUASAR program, said in a statement.

Approval of Tremfya was granted to Johnson & Johnson.

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-09-17 12:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords